While next-gen hep C treatment Sovaldi costs $84,000 per 12-week course of treatment, it boasts a 90% cure rate--and that's convinced the U.K.'s National Health Service to spend £18.7 million to fund the treatment for England's sickest patients.
On Tuesday, the Chinese government quietly announced that it is easing up on its policy of restricting drug prices and will allow pharmaceutical companies to set prices on some medicines, according to Reuters.
The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis. Not so much for consumers.
There could be a new attention disorder on the block in the future--one that could open up a new patient pool for ADHD drugmakers Eli Lilly, Shire and others. But with pharma critics adept at pointing fingers at companies for "disease-mongering," it's one that could open up a new round of controversy, too.
In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes from the second pharmacy benefits management report to be released in three days, this one from CVS Caremark following Express Scripts' missive on Tuesday.
The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.
Express Scripts released more stunning numbers on what could happen with spending on drugs to treat hepatitis C as it builds a case against the price Gilead Sciences has put on a drug that can cure the disease.
Pharma spent even less on digital advertising last year than in 2012, and the online share of DTC was already small to begin with.
A Johnson & Johnson number cruncher says nuggets of marketing gold are waiting to be found on its parenting site BabyCenter.
Express Scripts and Gilead Sciences are playing a high-priced game of chicken. At stake is the fate of Sovaldi (sofosbuvir), Gilead's high-priced hepatitis C pill, and the future of hep C treatment in the U.S. Not to mention the future of Sovaldi rivals from AbbVie, Bristol-Myers Squibb, and more.